<.p>Cognitive behavioral therapy for insomnia may significantly slow the pace of biological aging in older adults, according to findings published in The Lancet Healthy Longevity by researchers at UCLA Health.
Clinical Trial Design and Epigenetic Clocks
The study enrolled participants aged 60 and older who met diagnostic criteria for insomnia disorder, according to the research team at the Cousins Center for Psychoneuroimmunology at UCLA. Investigators assigned participants to one of two interventions: cognitive behavioral therapy for insomnia (CBT-I) or sleep education therapy (SET) as an active control group. CBT-I is a structured, multi-session psychological treatment designed to target specific thoughts and behaviors that perpetuate sleep problems. SET provides general informational content regarding sleep hygiene without targeted behavioral techniques.
Researchers extracted DNA from blood samples drawn before the eight-week treatment began and at follow-up visits conducted over a period of 20 to 39 months. To measure biological aging, the team utilized three distinct epigenetic clocks based on DNA methylation patterns, a molecular process that turns genes on or off:
- DunedinPACE: A sensitive clock designed to measure the real-time pace of biological aging.
- GrimAge: An epigenetic clock linked to lifespan and mortality risk.
- PC-PhenoAge: A clock estimating phenotypic age based on clinical biomarkers.
According to the results, adults who underwent CBT-I demonstrated a significantly slower pace of biological aging as measured by the DunedinPACE clock, with an effect size of -0.02 and an FDR-adjusted p-value of 0.03 compared to the control group. While GrimAge and PC-PhenoAge did not reach statistical significance, data trends favored the CBT-I group across those markers as well.
Insomnia Remission Rates and Longevity Implications
The trial also tracked clinical remission rates between the two cohorts. Dr. Judith Carroll, associate professor of psychiatry at UCLA Health and lead author of the study, noted that participants receiving CBT-I achieved a nearly three-fold greater likelihood of full insomnia remission. Specifically, CBT-I produced full remission in 34% of participants, compared to only 13% in the sleep education therapy group.
Clinical insomnia affects roughly 10% to 25% of adults over the age of 65 in the United States. Prior epidemiological research has established clear links between untreated clinical insomnia and advanced biological aging, which elevates the risk of age-related morbidities such as cardiovascular disease, type 2 diabetes, and overall mortality. By demonstrating that a behavioral, drug-free intervention modifies epigenetic aging markers, the findings reframe sleep therapy from a basic comfort measure into a potential longevity intervention.
Study Limitations and Next Steps
The research team outlined several constraints regarding the current findings. The trial relied on a modest sample size drawn from a single site in Los Angeles, California, and represented a secondary analysis of a trial registered under identifier NCT01641263, rather than a pre-registered primary endpoint.
Investigators stated that larger, multisite clinical trials involving more diverse participants across varying age brackets, races, and ethnicities are necessary to verify the results. Future research will also investigate whether treatment response differs by sex, or if alternative clinical approaches such as pharmacotherapy or Tai Chi produce comparable effects on cellular aging dynamics.
Worth a look